BioinfometricsBioinfometrics logo mark — DNA double helix encoded as a financial candlestick chart on an upward trend axis. The dual-read mark simultaneously represents molecular biology and market data intelligence.

Bioinfometrics

FDA Approves Sunharbo, a Factor XIa Inhibitor: Ischemic Stroke Down 26%, Major Bleeding Up 0.2 Points

The FDA approved Bayer asundexian on November 9. In 12,327 patients it lowered ischemic stroke from 8.4% to 6.2%, major bleeding was 1.9% against 1.7%, and lower gastrointestinal bleeding rose from 1.0% to 1.7%.

Illustration of a balance scale tipped down by a pile of pale weights on one side against a single small amber weight on the other
Martin DAVILABy Martin DAVILA11/17/20266

On November 9 the FDA approved Sunharbo (asundexian), Bayer's oral factor XIa inhibitor, to reduce the risk of stroke in adults after a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. It is number 48 on the FDA's list of novel drug approvals for 2026.

The question that decides whether a drug like this matters is simple: how many strokes does it prevent, and what does it cost in bleeding? The trial that supports the approval, OCEANIC-STROKE, answers both with numbers we can check.

What did the trial test?

OCEANIC-STROKE randomized 12,327 patients within 72 hours of a non-cardioembolic ischemic stroke or high-risk TIA. Half (6,162) received asundexian 50 mg once daily and half (6,165) received placebo, both on top of planned single or dual antiplatelet therapy. The primary efficacy outcome was ischemic stroke; the primary safety outcome was major bleeding.

This is a different group from the one in which the drug first failed. Bayer's earlier trial in atrial fibrillation, OCEANIC-AF, was stopped early. The approved indication is stroke or TIA of non-cardioembolic origin, not atrial fibrillation.

How large is the benefit, and how large is the bleeding cost?

Asundexian lowered ischemic stroke by 2.2 percentage points and left major bleeding within 0.2 points of placebo, but lower gastrointestinal bleeding rose from 1.0% to 1.7%.

Percentage of patients with each outcome in OCEANIC-STROKE. Efficacy: all 12,327 randomized. Bleeding: 12,254 treated (6,124 asundexian, 6,130 placebo). CRNM is clinically relevant non-major bleeding.

Asundexian 50 mgPlacebo

Source: Asundexian for Secondary Stroke Prevention, N Engl J Med 2026; OCEANIC-STROKE bleeding analysis, Circulation 2026. The stroke outcome and its hazard ratio (0.74, 95% CI 0.65 to 0.84) are from the NEJM abstract. Bleeding categories use ISTH definitions and a while-on-treatment analysis, from the Circulation paper. Lower GI bleeding: 102 patients on asundexian, 59 on placebo.

View data
outcomeasundexianplacebo
Ischemic stroke6.28.4
Major bleeding1.91.7
Major or CRNM bleeding5.55
Any bleeding12.512.3
Any GI bleeding32.4
Lower GI bleeding1.71

The efficacy result is clear. Ischemic stroke occurred in 6.2% of patients on asundexian and 8.4% on placebo, a cause-specific hazard ratio of 0.74 (95% CI 0.65 to 0.84, P below 0.001). That is a 26% relative reduction and 2.2 percentage points in absolute terms. Taking those rounded percentages at face value, about 45 patients would need treatment over the trial period to prevent one ischemic stroke. That is our arithmetic, not a figure the authors report.

On safety, major bleeding occurred in 117 patients (1.9%) on asundexian and 107 (1.7%) on placebo (hazard ratio 1.10, 95% CI 0.85 to 1.44, P=0.46). The interval includes no difference, and it also includes a 44% higher risk, so the trial does not rule out a modest increase. Symptomatic intracranial hemorrhage was 41 patients (0.7%) against 36 (0.6%).

Where did the extra bleeding show up?

Not in the headline categories. Any bleeding was almost identical (12.5% against 12.3%). The signal is in the gut: any gastrointestinal bleeding was 186 patients (3.0%) against 147 (2.4%), hazard ratio 1.28 (95% CI 1.03 to 1.59). Lower gastrointestinal bleeding was 102 (1.7%) against 59 (1.0%), hazard ratio 1.75 (95% CI 1.27 to 2.41), mostly rectal bleeding.

In per-1,000 terms, that is about 7 more lower-GI bleeds per 1,000 patients and about 2 more major bleeds per 1,000, against about 22 fewer ischemic strokes per 1,000. The trade is favorable on these numbers, which is presumably why the FDA approved it. It is not free, and the lower-GI result is a detail clinicians will want to see in the label.

Why does a factor XIa approval matter?

Factor XI sits in the intrinsic clotting pathway. The idea behind inhibiting it is that clots can be prevented with less effect on the clotting that stops ordinary bleeding. Reviews of the field describe a mixed record so far, with neutral phase 2 studies and the early termination of OCEANIC-AF. OCEANIC-STROKE is a phase 3 result in which the bleeding profile held up beside a clear efficacy gain, and an approved drug now exists to test that idea in routine care.

For people tracking the bioeconomy, the approval also lands in an already busy year. The FDA list stood at 46 novel approvals on October 9, as we covered in FDA Has Approved 46 Novel Drugs by October 9. Two more have followed on the agency's list: bepirovirsen on October 20 and Sunharbo on November 9.

What this does and does not show

The numbers show that, in this trial population, adding asundexian to antiplatelet therapy lowered ischemic stroke without a statistically significant rise in major bleeding. They do not show how the drug performs in older or sicker patients than those enrolled, in patients on other anticoagulants, or over years of use. The trial was funded by Bayer. We read the NEJM and Circulation abstracts rather than the full papers, so subgroup results, the length of follow-up and the exact definition of the time window are not covered here. As of November 16, ClinicalTrials.gov listed the study as completed (primary completion October 23, 2025) with no results posted in the registry. The 2.2-point difference and the 45 figure use rounded percentages and ignore how long patients were followed.

Sources

  1. FDA, Novel Drug Approvals for 2026: Sunharbo (asundexian), approved 11/9/2026, number 48; indication wording; Hibsago (bepirovirsen), 10/20/2026.
  2. Asundexian for Secondary Stroke Prevention, N Engl J Med 2026, doi:10.1056/NEJMoa2513880 (abstract read via Europe PMC): 12,327 randomized; 6.2% vs 8.4% ischemic stroke; hazard ratio 0.74; major bleeding 1.9% vs 1.7%.
  3. Bleeding With Asundexian Versus Placebo in Patients With Noncardioembolic Ischemic Stroke or High-Risk TIA, Circulation 2026, doi:10.1161/CIRCULATIONAHA.126.081836: all bleeding counts and hazard ratios.
  4. ClinicalTrials.gov, NCT05686070: enrollment 12,327, start January 26, 2023, primary completion October 23, 2025, results not posted as of November 16, 2026.
  5. FXI and FXII in experimental stroke and FXI in clinical stroke trials, Neurol Res Pract 2026: background on the early termination of OCEANIC-AF.
  6. Our earlier analysis: FDA Has Approved 46 Novel Drugs by October 9.

Found this article helpful? Share it with your network!

Recommended Reading

Discussion (0)

Sign in to join the conversation and share your thoughts

No comments yet. Be the first to start the discussion!